샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536132

세계 만성 피로 증후군 치료제 시장

Chronic Fatigue Syndrome Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 274 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

만성피로증후군치료제의 세계 시장은 2030년까지 2억 9,020만 달러에 달할 전망

2023년에 2억 3,990만 달러로 추정된 만성 피로 증후군 치료제 세계 시장은 2030년에는 2억 9,020만 달러에 이르고, 분석 기간 2023-2030년 CAGR은 2.8%로 성장할 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 진통제 & NSAIDs는 CAGR 4.1%로 성장을 지속하고, 분석 기간 종료 시 1억 3,750만 달러에 달할 것으로 예측됩니다. 항우울제 및 항정신병제 부문의 성장률은 분석 기간 동안 CAGR 1.9%로 추정됩니다.

미국 시장은 추정 6,540만 달러, 중국은 CAGR 5.7%로 성장 예측

미국의 만성피로증후군 치료제 시장은 2023년 6,540만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 5.7%로 성장하여 2030년에는 시장 규모가 5,940만 달러에 달할 것으로 예측되고 있습니다. 기타 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.7%와 2.1%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.4%로 성장할 것으로 예측됩니다.

세계의 만성 피로 증후군 치료제 시장 - 주요 촉진요인 및 동향 요약

근통성 뇌척수염(ME)으로도 알려진 만성 피로 증후군(CFS)은 휴식을 취해도 개선되지 않고 신체적 및 정신적 활동으로 악화되는 극도의 피로를 특징으로하는 복잡하고 쇠약성 질병입니다. 이 질환은 종종 근육통, 인지 장애, 수면장애, 두통 등 다양한 증상을 동반합니다. CFS의 정확한 원인은 알 수 없지만 유전적, 환경적, 심리적 요인이 결합되어 발생하는 것으로 간주됩니다. CFS 치료법은 현재 치료법이 없기 때문에 증상을 개선하고 삶의 질을 향상시키는 데 중점을 둡니다.

CFS의 치료법은 개인차가 크고, 약리학적, 비약리학적 접근을 조합하여 행할 수 있습니다. 약물 치료에는 진통제, 항우울제, 수면 도입제 등 특정 증상을 억제하기 위한 약물이 포함됩니다. 다른 특전으로는 특히 기초에 감염증이나 면역 기능 장애가 인정되는 경우에는 항바이러스약이나 면역조정 요법이 유효한 환자도 있습니다. 비약물 요법은 CFS 치료에 중요한 역할을 하고 있으며, 인지 행동 치료(CBT), 단계적 운동 요법(GET), 에너지 절약 및 스트레스 경감을 목적으로 한 생활 습관의 개선 등이 포함됩니다. 또한 증상을 완화하고 전반적인 건강 상태를 개선하기 위해 영양 지원, 침술, 명상 등의 보완 요법도 일반적으로 이루어지고 있습니다.

만성 피로 증후군 치료제 시장의 성장은 여러 요인에 의해 초래됩니다. 첫째, CFS의 인지도와 진단 증가는 인지도의 향상과 옹호 활동도 있어, 효과적인 치료에 대한 수요 증가로 이어지고 있습니다. 둘째, 의학 연구의 진보로 CFS의 복잡한 병태 생리가 점차 해명되고 있으며, 새로운 치료 대상과 치료 접근법에 대한 길이 열리고 있습니다. 또한 맞춤형 의료에 대한 관심 증가는 환자 프로파일에 맞는 치료가 가능하기 때문에 시장 성장에 기여하고 있습니다. 또한 신흥 시장에서 건강 관리 인프라를 확충하고 전문적인 치료에 접근하면 CFS 치료의 효과가 높아지고 있습니다. 제약회사와 연구기관의 전략적 제휴는 새로운 치료법의 개발을 가속화하고 있습니다. 게다가 디지털 헬스 기술의 대두는 환자의 관리 및 지원을 강화하여 증상 추적 및 치료 어드히어런스를 향상시키고 있습니다. 마지막으로, CFS 연구에 대한 자금 증가와 종합적인 임상 지침의 개발은 이러한 어려운 질병에 대한 보다 체계적이고 효과적인 접근을 촉진하고 있습니다.

조사 대상 기업 예(전 86건)

  • AIM ImmunoTech Inc.
  • Berlin Cures Holding AG
  • HiFiBiO Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Mitodicure GmbH
  • Mitsubishi Tanabe Pharma Corporation
  • Moleculera Biosciences
  • Novartis International AG
  • Otsuka Novel Products GmbH
  • Pfizer, Inc.
  • PrecisionLife Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tonix Pharmaceuticals Holding Corporation
  • Viatris, Inc.
  • Virios Therapeutics

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.29

Global Chronic Fatigue Syndrome Therapeutics Market to Reach US$290.2 Million by 2030

The global market for Chronic Fatigue Syndrome Therapeutics estimated at US$239.9 Million in the year 2023, is expected to reach US$290.2 Million by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Pain Relievers & NSAIDs, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$137.5 Million by the end of the analysis period. Growth in the Antidepressant & Antipsychotic Drugs segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$65.4 Million While China is Forecast to Grow at 5.7% CAGR

The Chronic Fatigue Syndrome Therapeutics market in the U.S. is estimated at US$65.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$59.4 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Chronic Fatigue Syndrome Therapeutics Market - Key Drivers and Trends Summarized

Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a complex and debilitating disorder characterized by extreme fatigue that does not improve with rest and is worsened by physical or mental activity. This condition often includes a range of symptoms such as muscle pain, cognitive difficulties, sleep disturbances, and headaches. The exact cause of CFS remains unknown, and it is believed to result from a combination of genetic, environmental, and psychological factors. Therapeutic approaches for CFS focus on managing symptoms and improving quality of life, as there is currently no cure for the condition.

Treatment strategies for CFS are highly individualized and may involve a combination of pharmacological and non-pharmacological approaches. Pharmacological treatments include medications to manage specific symptoms such as pain relievers, antidepressants, and sleep aids. Additionally, some patients benefit from antiviral medications or immune-modulating therapies, particularly if there is evidence of an underlying infection or immune dysfunction. Non-pharmacological treatments play a crucial role in CFS management and may include cognitive behavioral therapy (CBT), graded exercise therapy (GET), and lifestyle modifications aimed at energy conservation and stress reduction. Nutritional support and complementary therapies such as acupuncture and meditation are also commonly utilized to alleviate symptoms and enhance overall well-being.

The growth in the Chronic Fatigue Syndrome therapeutics market is driven by several factors. Firstly, increasing recognition and diagnosis of CFS, partly due to greater awareness and advocacy efforts, have led to a higher demand for effective treatments. Secondly, advancements in medical research are gradually unraveling the complex pathophysiology of CFS, paving the way for novel therapeutic targets and treatment approaches. The growing focus on personalized medicine is also contributing to market growth, as treatments can be tailored to individual patient profiles. Additionally, the expansion of healthcare infrastructure and access to specialized care in emerging markets is improving the availability of CFS treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new therapies. Furthermore, the rise of digital health technologies is enhancing patient management and support, facilitating better symptom tracking and treatment adherence. Lastly, increased funding for CFS research and the development of comprehensive clinical guidelines are fostering a more structured and effective approach to managing this challenging condition.

Select Competitors (Total 86 Featured) -

  • AIM ImmunoTech Inc.
  • Berlin Cures Holding AG
  • HiFiBiO Therapeutics
  • Mallinckrodt Pharmaceuticals
  • Mitodicure GmbH
  • Mitsubishi Tanabe Pharma Corporation
  • Moleculera Biosciences
  • Novartis International AG
  • Otsuka Novel Products GmbH
  • Pfizer, Inc.
  • PrecisionLife Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tonix Pharmaceuticals Holding Corporation
  • Viatris, Inc.
  • Virios Therapeutics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Chronic Fatigue Syndrome Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Awareness of Chronic Fatigue Syndrome (CFS) Drives Demand for Therapeutics
    • Advancements in Diagnostic Technologies Propel Growth in CFS Therapeutics Market
    • Growing Focus on Research and Development Expands Addressable Market Opportunity
    • Innovations in Symptom Management and Supportive Care Strengthen Business Case for Therapeutics
    • Increasing Focus on Holistic and Integrative Medicine Approaches Expands Market Opportunities
    • Enhanced Patient Outcomes Through Multidisciplinary Care Approaches Strengthen Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Fatigue Syndrome Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pain Relievers & NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pain Relievers & NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pain Relievers & NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antidepressant & Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antidepressant & Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antidepressant & Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antimicrobial & Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antimicrobial & Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antimicrobial & Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제